Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. reported strong growth and a return to profitability for the quarter ended June 30, 2026. Total revenue was 87,835 (in thousands), up 43% year over year, driven by services revenue of 80,692 and hardware revenue of 7,143 (both in thousands). Gross profit rose to 63,787 (in thousands), and gross margin expanded to 73%. The company generated net income of 5,294 (in thousands), compared with a loss of 5,311 (in thousands) a year earlier.
For the first half of 2026, revenue grew 43% to 165,883 (in thousands), with net income of 2,324 (in thousands). Membership expanded to 1,091,000 total members as of June 30, 2026. Partners affiliated with The Cigna Group remained highly significant, each representing over 30% of revenue. Omada ended the period with cash and cash equivalents of 221,712 (in thousands) and total assets of 328,222 (in thousands), with no preferred stock or warrant liabilities outstanding, while continuing to invest in research and development and sales and marketing to support platform and membership growth.
Omada Health, Inc. delivered strong results for the quarter ended June 30, 2026, with revenue of $88 million, up 43% year over year, and GAAP gross margin of 73%, a quarterly record. Net income was $5 million versus a $5 million loss in Q2 2025, and adjusted EBITDA reached a record $11 million. Total Members increased 45% year over year, trailing twelve‑month revenue per member was $284, and cash and cash equivalents totaled $222 million.
Full‑year 2026 guidance was raised to $334–$340 million of revenue and $21–$27 million of adjusted EBITDA, with midpoints implying 30% revenue growth and a fourfold increase in adjusted EBITDA versus 2025. Effective January 1, 2027, co‑founder Sean Duffy will become Founder and Executive Chair, President Wei‑Li Shao will assume the role of Chief Executive Officer and join the Board as a Class I director, and Jeryl Hilleman will become Lead Independent Director.
Omada Health, Inc. CEO Sean P. Duffy exercised stock options for 12,944 shares of common stock at $5.82 per share and on the same day sold 12,944 shares at a weighted average price of $20.3961 in open-market transactions between $20.15 and $20.58. The sale was executed under a Rule 10b5-1 trading plan adopted March 13, 2026. After the exercise, he held 142,483 options and 851,659 common shares indirectly through family trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
An affiliate of OMDA filed to potentially sell 12,944 shares of common stock through Morgan Stanley Smith Barney’s Executive Financial Services, following an exercise of stock options for cash on 08/03/2026, with sales expected on NASDAQ. The filing also lists several prior Rule 10b5-1 sales by Sean Duffy over the past three months, each specifying trade dates, share amounts, and dollar proceeds.
HILLEMAN JERYL L reported acquisition or exercise transactions in this Form 4 filing.
Omada Health, Inc. director Jeryl L. Hilleman received a grant of 1,435 restricted stock units of Common Stock on July 5, 2026 under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents one share, increasing her directly held beneficial ownership to 26,655 shares. This Form 4/A amends an earlier report that had understated both the RSU grant and resulting holdings due to an administrative error.
Omada Health, Inc. Chief Financial Officer Steven L. Cook exercised stock options for 12,150 shares of Common Stock at an exercise price of $8.28 per share, then sold 12,150 shares in open-market transactions at $24.0148 and $24.00 per share pursuant to a Rule 10b5-1 trading plan. Following these trades, he directly owned 187,209 shares of Common Stock.
Omada Health, Inc.'s Chief Accounting Officer, Gracey Craig, exercised stock options to acquire 1,041 shares of common stock at $6.57 per share and, on the same date, sold 1,041 shares in an open-market transaction at $24.00 per share pursuant to a 10b5-1 trading plan. Following these transactions, she holds 15,441 common shares directly and 33,334 stock options that remain outstanding.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported an exercise-and-sell transaction dated July 13, 2026. He exercised options for 5,800 common shares at $8.2800 per share and sold 5,800 common shares in open-market trades at $24.0100 and $24.0000 per share under a 10b5-1 trading plan, leaving 193,009 common shares held directly.
Steven Cook plans to sell 12,150 shares of OMDA common stock through Morgan Stanley Smith Barney LLC on NASDAQ around 07/15/2026. These shares are listed as acquired from the issuer via an exercise of stock options for cash on the same date. Over the past three months, Cook has already completed multiple 10b5-1 sales of OMDA common shares, with individual transactions ranging from 300 shares to 33,000 shares and reported dollar amounts reaching into the hundreds of thousands of dollars per trade.
Craig Gracey filed a notice to sell OMDA common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services. The filing covers 1,041 common shares, tied to an Exercise of Stock Options for cash, with a proposed sale date of 07/13/2026.
The filing also lists recent 10b5-1 Sales of OMDA common shares by Gracey, including transactions on 06/12/2026, 06/22/2026, 06/24/2026, 06/26/2026, 06/29/2026, 06/30/2026, and 07/01/2026, each specifying shares sold and total proceeds.